Vmbook Online ordering

Medgenics Inc

Medgenics, Inc. was a biopharmaceutical company that developed and commercialized regenerative medicine therapies. The company's proprietary technology platform allowed it to create and manufacture protein pharmaceuticals within the body, using autologous stem cells, to treat a range of chronic diseases.

Medgenics, Inc. was listed on the Nasdaq stock exchange under the ticker symbol "MGNI." However, it's important to note that the company is no longer in operation.

According to public records, Medgenics, Inc. was incorporated in 1992 and had its headquarters in Ohio, USA. The company's research and development efforts focused on the treatment of a variety of conditions, including hemophilia, cystic fibrosis, and diabetes.

Unfortunately, Medgenics, Inc. faced financial difficulties in recent years and was unable to sustain its operations. In 2017, the company announced that it would be delisted from the Nasdaq stock exchange due to its inability to maintain the minimum bid price requirement. Later that year, Medgenics, Inc. filed for Chapter 7 bankruptcy protection and ceased its operations.

At this point, any further information about Medgenics, Inc. would likely be historical and related to its prior operations, research, and development efforts.